Corixa Corp.'s stock headed upward Tuesday following news that the FDA accepted additional data as well as responses to concerns raised about the biologics license application for Bexxar, the company's lead cancer product, and thus Corixa dropped its dispute resolution with the FDA. (BioWorld Today)
Corixa Corp.'s stock headed upward Tuesday following news that the FDA accepted additional data as well as responses to concerns raised about the biologics license application for Bexxar, the company's lead cancer product, and thus Corixa dropped its dispute resolution with the FDA. (BioWorld Today)
At the 75th American Heart Association's Scientific Sessions in Chicago, CV Therapeutics Inc. presented data from a Phase III trial of a drug that exceeded the company's expectations in its ability to convert an abnormally rapid heart rhythm back to normal. (BioWorld Today)
At the 75th American Heart Association's Scientific Sessions in Chicago, CV Therapeutics Inc. presented data from a Phase III trial of a drug that exceeded the company's expectations in its ability to convert an abnormally rapid heart rhythm back to normal. (BioWorld Today)
